Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 3/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699576 | 0.89 | POLA1 (0.42) | KCNH2POLA1 | |
| SCHEMBL6669974 | 0.87 | MAPK1 (0.37) | KCNH2MAPK1POLA1EGLN1KMT2A | |
| SCHEMBL6669028 | 0.86 | MAPK1 (0.39) | KCNH2MAPK1POLA1EGLN1KMT2A | |
| SCHEMBL6691671 | 0.85 | CACNA1C (0.35) | CACNA1CSCN5AKCNH2MAPK1POLA1 | |
| SCHEMBL6700225 | 0.85 | POLA1 (0.35) | CACNA1CSCN5AKCNH2POLA1MEN1 | |
| SCHEMBL6667328 | 0.83 | MAPK1 (0.37) | KCNH2MAPK1POLA1EGLN1MEN1 | |
| SCHEMBL6669484 | 0.81 | MAPK1 (0.36) | MAPK1POLA1EGLN1MEN1KMT2A | |
| SCHEMBL6667340 | 0.80 | PTGER4 (0.34) | MAPK1EGLN1MEN1KMT2A | |
| SCHEMBL6669978 | 0.76 | MAPK1 (0.38) | KCNH2MAPK1EGLN1KMT2A | |
| SCHEMBL6695866 | 0.76 | NPC1 (0.33) | KCNH2MAPK1POLA1EGLN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | claimed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | claimed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | claimed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | claimed |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | WATHEN MICHAEL W | 2004-04-08 | — | — | US | disclosed |
| EP-1265872-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6458788-B1 | VIRICIDES; HERPES VIRUS | PHARMACIA & UPJOHN COMPANY | 2002-10-01 | — | — | US | disclosed |
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2001081318-A1 | 4-HYDROXYCINNOLINE-3-CARBOXYAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042397-A1 | 4-hydroxycinnoline-3-carboxyamides as antiviral agents | HAVCR2, ZC3HAV1, HCFC1 | CACNA1C 1062/4885SCN5A 2566/4885KCNH2 1186/4885 |
| US-20040067947-A1 | Method of preventing or treating atherosclerosis or restenosis | LDLR, MSR1, NR1H2 | CACNA1C 3984/4885SCN5A 4332/4885KCNH2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.